Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zemplar in CKD Stage 5 with Secondary Hyperparathyroidism
NCT00091975Phase 3Completed
- Sponsor
- Abbott Laboratories
- Start
- Aug 2004
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in secondary hyperparathyroidism (SHPT) comparing Zemplar with Placebo (2 arms). Primary endpoint: Achievement of two consecutive >= 30% decreases from baseline in iPTH levels. Started Aug 2004; status: completed.
02
Drugs
paricalcitol oral solution
03
Conditions
secondary hyperparathyroidism (SHPT)
Beyond the preview
Go deeper on NCT00091975.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00091975.